Marcie D Haydon1, Annette L Stanton1,2,3,4, Patricia A Ganz3,5, Julienne E Bower1,2,3,4. 1. a Department of Psychology , University of California, Los Angeles, (UCLA) , Los Angeles , California , USA. 2. b Department of Psychiatry and Biobehavioral Sciences , UCLA , Los Angeles , California , USA. 3. c Jonsson Comprehensive Cancer Center, UCLA , Los Angeles , California , USA. 4. d Cousins Center for Psychoneuroimmunology, UCLA , Los Angeles , California , USA. 5. e Schools of Medicine and Public Health , UCLA , Los Angeles , California , USA.
Abstract
PURPOSE: Cancer-related goal disturbance can influence long-term outcomes in cancer patients and survivors; however, few studies have examined the factors that contribute to goal disturbance in early survivorship. DESIGN: The current study examined the relationships between demographic variables, cancer- and treatment-related factors, and behavioral and psychological symptoms (i.e., fatigue, pain, cognitive complaints, depressive symptoms, and anxiety) and goal disturbance in breast cancer survivors 1 year after treatment completion. METHODS: Women diagnosed with early-stage breast cancer (n = 171) completed assessments following primary treatment (i.e., surgery, radiation, and chemotherapy) and again 6 months and 1 year later. We focused on the 1-year post-treatment assessment when participants were asked if they had experienced a cancer-related goal disturbance. FINDINGS: Approximately, 27% of women reported a cancer-related goal disturbance. Analyses indicated that both receipt of chemotherapy and behavioral and psychological symptoms-analyzed as a composite score and individually-were associated with a higher probability of reporting a goal disturbance. CONCLUSIONS: Chemotherapy and behavioral and psychological symptoms were unique correlates of goal disturbance, suggesting that the impact of chemotherapy extends beyond its influence on persistent symptoms. IMPLICATIONS: Elucidating factors that inhibit the pursuit of meaningful activities in early survivorship is critically important to understanding the long-term psychosocial impacts of cancer diagnosis and treatment.
PURPOSE:Cancer-related goal disturbance can influence long-term outcomes in cancerpatients and survivors; however, few studies have examined the factors that contribute to goal disturbance in early survivorship. DESIGN: The current study examined the relationships between demographic variables, cancer- and treatment-related factors, and behavioral and psychological symptoms (i.e., fatigue, pain, cognitive complaints, depressive symptoms, and anxiety) and goal disturbance in breast cancer survivors 1 year after treatment completion. METHODS:Women diagnosed with early-stage breast cancer (n = 171) completed assessments following primary treatment (i.e., surgery, radiation, and chemotherapy) and again 6 months and 1 year later. We focused on the 1-year post-treatment assessment when participants were asked if they had experienced a cancer-related goal disturbance. FINDINGS: Approximately, 27% of women reported a cancer-related goal disturbance. Analyses indicated that both receipt of chemotherapy and behavioral and psychological symptoms-analyzed as a composite score and individually-were associated with a higher probability of reporting a goal disturbance. CONCLUSIONS: Chemotherapy and behavioral and psychological symptoms were unique correlates of goal disturbance, suggesting that the impact of chemotherapy extends beyond its influence on persistent symptoms. IMPLICATIONS: Elucidating factors that inhibit the pursuit of meaningful activities in early survivorship is critically important to understanding the long-term psychosocial impacts of cancer diagnosis and treatment.
Entities:
Keywords:
Behavioral symptoms; breast cancer; early survivorship; goal disturbance
Authors: G A Curt; W Breitbart; D Cella; J E Groopman; S J Horning; L M Itri; D H Johnson; C Miaskowski; S L Scherr; R K Portenoy; N J Vogelzang Journal: Oncologist Date: 2000
Authors: Julienne E Bower; Patricia A Ganz; Katherine A Desmond; Coen Bernaards; Julia H Rowland; Beth E Meyerowitz; Thomas R Belin Journal: Cancer Date: 2006-02-15 Impact factor: 6.860
Authors: Patricia A Ganz; Gail A Greendale; Laura Petersen; Barbara Kahn; Julienne E Bower Journal: J Clin Oncol Date: 2003-11-15 Impact factor: 44.544
Authors: Michael A Hoyt; Ashley Wei-Ting Wang; Sean J Ryan; Elizabeth C Breen; Jennifer S Cheavens; Christian J Nelson Journal: Trials Date: 2020-04-14 Impact factor: 2.279